ClinicalTrials.gg

TargetBeta

ROR1

ROR family WNT receptor 1 · also NTRKR1 · I-set domain containing

5 programs in company-led studies act on ROR1, from 5 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
zilovertamab vedotinMerckphase 3107 running–a judged reading
Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07ruleShanghai EpimAb Biotherapeuticsphase 222 runningCD3ENCIt
TQB2101Sino Biopharmaceuticalphase 122 running–the company's pipeline
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleNEOK Biophase 111 runningCD276NCIt
Anti-ROR1 Antibody-drug Conjugate IM-1021ruleImmunomephase 111 running–NCIt

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.